公开(公告)号：EP1259485B1

公开(公告)日：2005-11-30

申请号：EP01918257.5

申请日：2001-02-28

申请人： MILLENNIUM PHARMACEUTICALS, INC.

发明人： ZHU, Bing-Yan ,  ZHANG, Penglie ,  WANG, Lingyan ,  HUANG, Wenrong ,  GOLDMAN, Erick ,  LI, Wenhao ,  ZUCKETT, Jingmei ,  SONG, Yonghong ,  SCARBOROUGH, Robert

IPC分类号： C07D213/75 ,  C07D401/12 ,  A61K31/44 ,  A61P7/02

CPC分类号： A61K31/44 ,  A61K9/20 ,  A61K9/2013 ,  A61K9/2054 ,  A61K9/48 ,  A61K9/4858 ,  A61K9/4866 ,  A61K31/616 ,  A61K45/06 ,  A61K2201/094 ,  C07C237/42 ,  C07C255/60 ,  C07C257/18 ,  C07C259/18 ,  C07C311/16 ,  C07C311/46 ,  C07C317/40 ,  C07C317/44 ,  C07D213/75 ,  C07D213/81 ,  C07D213/82 ,  C07D217/22 ,  C07D231/12 ,  C07D233/56 ,  C07D233/64 ,  C07D249/08 ,  C07D295/125 ,  C07D333/38 ,  C07D401/12 ,  C07D409/12 ,  C07D409/14

摘要： Novel benzamide compounds including their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalian factor Xa are described Compositions containing such compounds are also described The compounds and compositions are useful in vitro or in vivo for preventing or treating coagulation disorders

公开(公告)号：EP1259485A2

公开(公告)日：2002-11-27

申请号：EP01918257.5

申请日：2001-02-28

申请人： Millennium Pharmaceuticals, Inc.

发明人： ZHU, Bing-Yan ,  ZHANG, Penglie ,  WANG, Lingyan ,  HUANG, Wenrong ,  GOLDMAN, Erick ,  LI, Wenhao ,  ZUCKETT, Jingmei ,  SONG, Yonghong ,  SCARBOROUGH, Robert

IPC分类号： C07D213/75 ,  C07D401/12 ,  A61K31/44 ,  A61P7/02

CPC分类号： A61K31/44 ,  A61K9/20 ,  A61K9/2013 ,  A61K9/2054 ,  A61K9/48 ,  A61K9/4858 ,  A61K9/4866 ,  A61K31/616 ,  A61K45/06 ,  A61K2201/094 ,  C07C237/42 ,  C07C255/60 ,  C07C257/18 ,  C07C259/18 ,  C07C311/16 ,  C07C311/46 ,  C07C317/40 ,  C07C317/44 ,  C07D213/75 ,  C07D213/81 ,  C07D213/82 ,  C07D217/22 ,  C07D231/12 ,  C07D233/56 ,  C07D233/64 ,  C07D249/08 ,  C07D295/125 ,  C07D333/38 ,  C07D401/12 ,  C07D409/12 ,  C07D409/14

摘要： Novel benzamide compounds including their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalian factor Xa are described Compositions containing such compounds are also described The compounds and compositions are useful in vitro or in vivo for preventing or treating coagulation disorders